文献速递前列腺癌

17基因基因组前列腺评分在非裔美国与白人男性局限性前列腺癌中的多中心比较

Multicenter Comparison of 17-Gene Genomic Prostate Score as a Predictor of Outcomes in African American and Caucasian American Men with Clinically Localized Prostate Cancer.
PubMed 文献 · J Urol · 2020-12-01

该回顾性多中心研究比较了Oncotype DX基因组前列腺评分(GPS)在201例非裔美国男性和1,144例白人男性局限性前列腺癌中的表现。结果显示GPS与不良病理和生化复发显著相关,而种族不是独立预测因子,提示该检测在不同种族中预测效能相似。

要点

  • GPS在非裔美国与白人男性中均与不良病理(p≤0.004)和生化复发(p<0.001)显著相关。
  • 种族不是不良病理或生化复发的显著预测因子。
  • GPS可改善两个种族新诊断前列腺癌患者的风险分层。

核心结论

  • Oncotype DX GPS检测在非裔美国和白人男性中对不良病理和生化复发具有相似预测效能,并改善两组的风险分层。

研究设计与样本

  • 回顾性分析6个队列中201例非裔美国男性和1,144例白人男性接受手术治疗的临床局限性前列腺癌患者。
  • 比较活检标本的GPS结果(0-100分)和4个基因组评分,不良病理定义为高级别(原发Gleason模式4或任何模式5)和/或非器官局限(≥pT3)。
  • 采用二元逻辑回归分析不良病理,Cox比例风险模型评估生化复发(连续两次PSA>0.2 ng/ml或根治性前列腺切除术后启动挽救治疗)。

主要发现

  • 各队列临床风险分布和非裔美国人比例不同,但两个种族的GPS中位数和四分位距及基因组评分相似。
  • 在多变量模型中纳入检测、病理/临床特征和种族后,检测与不良病理显著相关(p≤0.004),与生化复发显著相关(p<0.001)。
  • 种族对两个终点均不是显著预测因子。

关键数值与推荐

  • 不良病理定义:高级别(原发Gleason模式4或任何模式5)和/或非器官局限(≥pT3)。
  • 生化复发定义:连续两次PSA>0.2 ng/ml或根治性前列腺切除术后启动挽救治疗。
  • GPS评分范围0-100分。

临床怎么用

  • GPS可用于非裔美国和白人局限性前列腺癌患者的风险分层,辅助治疗决策。
  • 解读GPS结果时无需因种族差异而调整预测价值。

局限性

  • 回顾性研究设计。
  • 各队列临床风险分布和非裔美国人比例存在差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Adoption of prognostic molecular assays for prostate cancer requires evidence of robust performance in different racial groups. Retrospective analysis was conducted to assess the performance of the Oncotype DX® Genomic Prostate Score® test in African American and Caucasian American men with surgically treated prostate cancer. MATERIALS AND METHODS: We compared the assay results (scale 0-100) and the 4 gene group scores in biopsy specimens from 201 African American and 1,144 Caucasian American men with clinically localized prostate cancer in 6 cohorts. Adverse pathology was defined as high grade (primary Gleason pattern 4 or any pattern 5) and/or nonorgan-confined disease (≥pT3). Binary logistic regression models were used for adverse pathology. Biochemical recurrence was defined as 2 successive prostate specific antigen levels >0.2 ng/ml or initiation of salvage therapy after radical prostatectomy. Cox proportional hazards models evaluated the association of the assay result or racial group with time to biochemical recurrence. RESULTS: Each cohort had different clinical risk distributions and percentages of African Americans, although median and interquartile ranges of the assay results and gene group scores were similar between both racial groups. In a multivariable model with the assay and pathological/clinical features including race, the assay was significantly associated with adverse pathology (p ≤0.004) and biochemical recurrence (p <0.001). Race was not a significant predictor of either end point. CONCLUSIONS: The assay is similarly predictive of outcomes in African American and Caucasian American patients, and improves risk stratification in men with newly diagnosed prostate cancer from both racial groups.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Cullen J, Lynch JA, Klein EA, et al. Multicenter Comparison of 17-Gene Genomic Prostate Score as a Predictor of Outcomes in African American and Caucasian American Men with Clinically Localized Prostate Cancer. J Urol. 2020. PMID: 33493001. doi:10.1097/JU.0000000000001484

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。